All Archives - Page 9 of 15

All Features

Lonza announces collaboration with BaseLaunch

Lonza works to enable a healthier world by supporting customers to deliver new and innovative medicines that help treat a wide range of diseases. Their…

Arianna23.06.2022

All Features

14 legal questions every biotech startup should ask

Walder Wyss is one of the most successful and fastest-growing Swiss law ﬁrms. Since March 2021, they’re also one of our domain partners. Dr. iur.,…

Arianna17.06.2022

Anaveon_-startups_Switzerland-credit-Jasmin-Rei

All Portfolio news

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…

Arianna10.06.2022

All Portfolio news

Onena Medicines joins BaseLaunch Portfolio

We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…

Arianna11.05.2022

All Portfolio news

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…

Arianna03.05.2022

All Portfolio news

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…

Arianna13.04.2022

All Features

File or fail in the age of publish or perish

When is the right time to file a patent? The decision of when to file a patent application depends on a combination of business and…

Arianna28.02.2022

All Features

Your first European launch: a prescription for growth

For non-European biopharmaceutical companies, launching a drug in the EU can be extremely challenging. but, with the right drug and a clear strategy, it can…

Arianna28.02.2022

All Portfolio news

BaseLaunch – onwards and upwards

2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…

Arianna28.02.2022

All Portfolio news

Aukera Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…

Arianna15.02.2022

All

Lonza announces collaboration with BaseLaunch

14 legal questions every biotech startup should ask

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

Onena Medicines joins BaseLaunch Portfolio

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

File or fail in the age of publish or perish

Your first European launch: a prescription for growth

BaseLaunch – onwards and upwards

Aukera Therapeutics joins BaseLaunch Portfolio

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us